O	0	4	Long	Long	JJ	B-NP
O	4	5	-	-	HYPH	I-NP
O	5	9	term	term	NN	I-NP
O	10	27	immunosuppression	immunosuppression	NN	I-NP
O	28	30	in	in	IN	B-PP
O	31	37	burned	burn	VBN	B-NP
O	38	46	patients	patient	NNS	I-NP
O	47	55	assessed	assess	VBN	B-VP
O	56	58	by	by	IN	B-PP
O	59	61	in	in	FW	B-NP
O	62	67	vitro	vitro	FW	I-NP
B-Cell	68	78	neutrophil	neutrophil	NN	I-NP
O	79	88	oxidative	oxidative	JJ	I-NP
O	89	94	burst	burst	NN	I-NP
O	95	96	(	(	(	O
O	96	106	Phagoburst	Phagoburst	NN	B-NP
O	106	107	)	)	)	O
O	107	108	.	.	.	O

O	109	118	OBJECTIVE	OBJECTIVE	NN	B-NP
O	118	119	:	:	:	O

O	120	122	To	To	TO	B-VP
O	123	129	assess	assess	VB	I-VP
O	130	133	the	the	DT	B-NP
O	134	142	duration	duration	NN	I-NP
O	143	146	and	and	CC	I-NP
O	147	156	magnitude	magnitude	NN	I-NP
O	157	159	of	of	IN	B-PP
O	160	177	immunosuppression	immunosuppression	NN	B-NP
O	178	185	induced	induce	VBN	B-VP
O	186	188	by	by	IN	B-PP
O	189	194	burns	burn	NNS	B-NP
O	195	197	as	as	IN	B-SBAR
O	198	206	measured	measure	VBN	B-VP
O	207	209	by	by	IN	B-PP
O	210	213	the	the	DT	B-NP
B-Cell	214	224	neutrophil	neutrophil	NN	I-NP
O	225	234	oxidative	oxidative	JJ	I-NP
O	235	240	burst	burst	NN	I-NP
O	241	243	in	in	FW	B-ADVP
O	244	249	vitro	vitro	FW	I-ADVP
O	249	250	.	.	.	O

O	251	257	DESIGN	DESIGN	NN	B-NP
O	257	258	:	:	:	O

O	259	270	Prospective	Prospective	JJ	B-NP
O	271	282	exploratory	exploratory	JJ	I-NP
O	283	289	cohort	cohort	JJ	I-NP
O	290	295	study	study	NN	I-NP
O	295	296	.	.	.	O

O	297	304	SETTING	SETTING	NN	B-NP
O	304	305	:	:	:	O

O	306	314	Tertiary	Tertiary	JJ	B-NP
O	315	323	referral	referral	JJ	I-NP
O	324	328	unit	unit	NN	I-NP
O	328	329	,	,	,	O
O	330	340	University	University	NNP	B-NP
O	341	349	Hospital	Hospital	NNP	I-NP
O	349	350	,	,	,	O
O	351	360	Linkoping	Linkoping	NNP	B-NP
O	360	361	,	,	,	O
O	362	368	Sweden	Sweden	NNP	B-NP
O	369	370	(	(	(	O
O	370	378	National	National	NNP	B-NP
O	379	383	Burn	Burn	NNP	I-NP
O	384	388	Unit	Unit	NNP	I-NP
O	388	389	)	)	)	O
O	389	390	.	.	.	O

O	391	399	PATIENTS	PATIENTS	NNS	B-NP
O	400	403	AND	AND	CC	I-NP
O	404	411	HEALTHY	HEALTHY	NN	I-NP
O	412	422	VOLUNTEERS	VOLUNTEERS	NNS	I-NP
O	423	424	(	(	(	O
O	424	432	CONTROLS	CONTROLS	NN	B-NP
O	432	433	)	)	)	O
O	433	434	:	:	:	O
O	435	441	Twenty	Twenty	CD	B-NP
O	441	442	-	-	HYPH	I-NP
O	442	447	eight	eight	CD	I-NP
O	448	456	subjects	subject	NNS	I-NP
O	457	470	consecutively	consecutively	RB	B-VP
O	471	479	admitted	admit	VBN	I-VP
O	480	482	to	to	TO	B-PP
O	483	486	the	the	DT	B-NP
O	487	491	Burn	Burn	NNP	I-NP
O	492	496	Unit	Unit	NNP	I-NP
O	496	497	.	.	.	O

O	498	501	The	The	DT	B-NP
O	502	506	mean	mean	JJ	I-NP
O	507	512	total	total	JJ	I-NP
O	513	517	burn	burn	NN	I-NP
B-Tissue	518	525	surface	surface	NN	I-NP
I-Tissue	526	530	area	area	NN	I-NP
O	531	532	(	(	(	O
O	532	536	TBSA	TBSA	NN	B-NP
O	536	537	%	%	NN	I-NP
O	537	538	)	)	)	O
O	539	542	was	be	VBD	B-VP
O	543	545	36	36	CD	B-NP
O	546	547	(	(	(	O
O	547	552	range	range	NN	B-NP
O	553	555	13	13	CD	I-NP
O	555	556	-	-	HYPH	B-NP
O	556	558	87	87	CD	I-NP
O	558	559	)	)	)	O
O	560	563	and	and	CC	O
O	564	568	mean	mean	JJ	B-NP
O	569	572	age	age	NN	I-NP
O	573	575	44	44	CD	B-NP
O	576	581	years	year	NNS	I-NP
O	582	583	(	(	(	O
O	583	588	range	range	NN	B-NP
O	589	591	14	14	CD	I-NP
O	591	592	-	-	HYPH	B-NP
O	592	594	89	89	CD	I-NP
O	594	595	)	)	)	O
O	595	596	.	.	.	O

O	597	605	Patients	Patient	NNS	B-NP
O	605	606	'	'	POS	B-NP
O	607	611	data	datum	NNS	I-NP
O	612	616	were	be	VBD	B-VP
O	617	626	collected	collect	VBN	I-VP
O	627	640	prospectively	prospectively	RB	B-ADVP
O	641	643	in	in	IN	B-PP
O	644	647	the	the	DT	B-NP
O	648	652	burn	burn	NN	I-NP
O	653	657	unit	unit	NN	I-NP
O	657	658	,	,	,	O
O	659	664	which	which	WDT	B-NP
O	665	669	also	also	RB	B-ADVP
O	670	678	included	include	VBD	B-VP
O	679	689	sequential	sequential	JJ	B-NP
B-Organ	690	695	organ	organ	NN	I-NP
O	696	703	failure	failure	NN	I-NP
O	704	714	assessment	assessment	NN	I-NP
O	715	716	(	(	(	O
O	716	720	SOFA	SOFA	NN	B-NP
O	720	721	)	)	)	O
O	722	727	score	score	NN	B-NP
O	727	728	.	.	.	O

O	729	742	INTERVENTIONS	INTERVENTIONS	NNS	B-NP
O	742	743	:	:	:	O

O	744	748	None	None	NN	B-NP
O	748	749	.	.	.	O

O	750	762	MEASUREMENTS	MEASUREMENTS	NNS	B-NP
O	763	766	AND	AND	CC	I-NP
O	767	774	RESULTS	RESULTS	NNS	I-NP
O	774	775	:	:	:	O

O	776	778	To	To	TO	B-VP
O	779	785	assess	assess	VB	I-VP
O	786	789	the	the	DT	B-NP
O	790	797	changes	change	NNS	I-NP
O	798	800	in	in	IN	B-PP
O	801	804	the	the	DT	B-NP
O	805	814	oxidative	oxidative	JJ	I-NP
O	815	823	capacity	capacity	NN	I-NP
O	824	826	of	of	IN	B-PP
B-Cell	827	838	neutrophils	neutrophil	NNS	B-NP
O	839	844	after	after	IN	B-PP
O	845	848	the	the	DT	B-NP
O	849	853	burn	burn	NN	I-NP
O	853	854	,	,	,	O
B-Organism_substance	855	860	blood	blood	NN	B-NP
I-Organism_substance	861	868	samples	sample	NNS	I-NP
O	869	872	for	for	IN	B-PP
O	873	876	the	the	DT	B-NP
O	877	887	Phagoburst	Phagoburst	NNP	I-NP
O	888	896	analysis	analysis	NN	I-NP
O	897	901	were	be	VBD	B-VP
O	902	907	taken	take	VBN	I-VP
O	908	910	on	on	IN	B-PP
O	911	920	admission	admission	NN	B-NP
O	921	924	and	and	CC	O
O	925	927	at	at	IN	B-ADVP
O	928	933	least	least	JJS	I-ADVP
O	934	938	once	once	RB	I-ADVP
O	939	944	every	every	DT	B-NP
O	945	951	second	second	JJ	I-NP
O	952	956	week	week	NN	I-NP
O	957	960	for	for	IN	B-PP
O	961	964	the	the	DT	B-NP
O	965	973	duration	duration	NN	I-NP
O	974	976	of	of	IN	B-PP
O	977	981	stay	stay	NN	B-NP
O	982	984	in	in	IN	B-PP
O	985	993	hospital	hospital	NN	B-NP
O	994	997	and	and	CC	O
O	998	1008	thereafter	thereafter	RB	B-ADVP
O	1009	1016	monthly	monthly	RB	I-ADVP
O	1017	1019	up	up	IN	B-NP
O	1020	1022	to	to	TO	I-NP
O	1023	1025	12	12	CD	I-NP
O	1026	1032	months	month	NNS	I-NP
O	1033	1038	after	after	IN	B-SBAR
O	1039	1042	the	the	DT	B-NP
O	1043	1047	burn	burn	NN	I-NP
O	1047	1048	.	.	.	O

B-Cell	1049	1060	Neutrophils	Neutrophil	NNS	B-NP
O	1061	1065	were	be	VBD	B-VP
O	1066	1076	stimulated	stimulate	VBN	I-VP
O	1077	1079	in	in	FW	B-ADVP
O	1080	1085	vitro	vitro	FW	I-ADVP
O	1086	1088	by	by	IN	B-PP
O	1089	1100	Escherichia	Escherichia	FW	B-NP
O	1101	1105	coli	coli	FW	I-NP
O	1105	1106	,	,	,	O
O	1107	1114	phorbol	phorbol	NN	B-NP
O	1115	1117	12	12	CD	I-NP
O	1117	1118	-	-	HYPH	B-NP
O	1118	1125	phorbol	phorbol	NN	I-NP
O	1126	1135	myristate	myristate	NN	I-NP
O	1136	1138	13	13	CD	I-NP
O	1138	1139	-	-	HYPH	O
O	1139	1146	acetate	acetate	NN	B-NP
O	1147	1148	(	(	(	O
O	1148	1151	PMA	PMA	NN	B-NP
O	1151	1152	)	)	)	O
O	1152	1153	,	,	,	O
O	1154	1157	and	and	CC	O
O	1158	1165	peptide	peptide	NN	B-NP
O	1166	1167	N	N	NN	I-NP
O	1167	1168	-	-	HYPH	B-NP
O	1168	1174	formyl	formyl	NN	I-NP
O	1174	1175	-	-	HYPH	B-NP
O	1175	1178	Met	Met	NN	I-NP
O	1178	1179	-	-	HYPH	B-NP
O	1179	1182	Leu	Leu	NN	I-NP
O	1182	1183	-	-	HYPH	O
O	1183	1186	Phe	Phe	NN	B-NP
O	1187	1188	(	(	(	O
O	1188	1192	fMLP	fMLP	NN	B-NP
O	1192	1193	)	)	)	O
O	1193	1194	.	.	.	O

O	1195	1204	Oxidative	Oxidative	JJ	B-NP
O	1205	1210	burst	burst	NN	I-NP
O	1211	1214	was	be	VBD	B-VP
O	1215	1223	measured	measure	VBN	I-VP
O	1224	1226	by	by	IN	B-PP
O	1227	1231	flow	flow	NN	B-NP
O	1232	1241	cytometry	cytometry	NN	I-NP
O	1241	1242	.	.	.	O

O	1243	1252	Oxidative	Oxidative	JJ	B-NP
O	1253	1261	capacity	capacity	NN	I-NP
O	1262	1264	of	of	IN	B-PP
O	1265	1268	the	the	DT	B-NP
B-Cell	1269	1280	neutrophils	neutrophil	NNS	I-NP
O	1281	1290	decreased	decrease	VBD	B-VP
O	1291	1300	similarly	similarly	RB	B-ADVP
O	1301	1304	for	for	IN	B-PP
O	1305	1308	all	all	DT	B-NP
O	1309	1314	three	three	CD	I-NP
O	1315	1325	stimulants	stimulant	NNS	I-NP
O	1325	1326	:	:	:	O
O	1327	1332	there	there	EX	B-NP
O	1333	1336	was	be	VBD	B-VP
O	1337	1338	a	a	DT	B-NP
O	1339	1351	pathological	pathological	JJ	I-NP
O	1352	1360	decrease	decrease	NN	I-NP
O	1361	1368	shortly	shortly	RB	B-ADVP
O	1369	1374	after	after	IN	B-PP
O	1375	1384	admission	admission	NN	B-NP
O	1384	1385	,	,	,	O
O	1386	1390	with	with	IN	B-PP
O	1391	1394	the	the	DT	B-NP
O	1395	1401	lowest	low	JJS	I-NP
O	1402	1407	value	value	NN	I-NP
O	1408	1417	occurring	occur	VBG	B-VP
O	1418	1425	between	between	IN	B-PP
O	1426	1430	days	day	NNS	B-NP
O	1431	1432	7	7	CD	B-NP
O	1433	1436	and	and	CC	I-NP
O	1437	1439	10	10	CD	I-NP
O	1439	1440	,	,	,	O
O	1441	1449	followed	follow	VBN	B-VP
O	1450	1452	by	by	IN	B-PP
O	1453	1454	a	a	DT	B-NP
O	1455	1462	gradual	gradual	JJ	I-NP
O	1463	1471	recovery	recovery	NN	I-NP
O	1472	1478	during	during	IN	B-PP
O	1479	1482	the	the	DT	B-NP
O	1483	1490	ensuing	ensue	VBG	I-NP
O	1491	1497	months	month	NNS	I-NP
O	1497	1498	.	.	.	O

O	1499	1503	Full	Full	JJ	B-NP
O	1504	1512	recovery	recovery	NN	I-NP
O	1513	1514	(	(	(	O
O	1514	1516	to	to	TO	B-PP
O	1517	1520	the	the	DT	B-NP
O	1521	1527	values	value	NNS	I-NP
O	1528	1530	of	of	IN	B-PP
O	1531	1534	the	the	DT	B-NP
O	1535	1543	controls	control	NNS	I-NP
O	1543	1544	)	)	)	O
O	1545	1548	was	be	VBD	B-VP
O	1549	1553	seen	see	VBN	I-VP
O	1554	1559	first	first	RB	B-ADVP
O	1560	1561	3	3	CD	B-NP
O	1561	1562	.	.	.	O
O	1562	1563	5	5	CD	B-NP
O	1564	1570	months	month	NNS	I-NP
O	1571	1576	after	after	IN	B-SBAR
O	1577	1580	the	the	DT	B-NP
O	1581	1585	burn	burn	NN	I-NP
O	1585	1586	.	.	.	O

O	1587	1592	Using	Use	VBG	B-VP
O	1593	1601	multiple	multiple	JJ	B-NP
O	1602	1612	regression	regression	NN	I-NP
O	1612	1613	,	,	,	O
O	1614	1616	we	we	PRP	B-NP
O	1617	1622	found	find	VBD	B-VP
O	1623	1627	that	that	IN	B-SBAR
O	1628	1632	only	only	RB	B-NP
O	1633	1636	age	age	NN	I-NP
O	1637	1640	and	and	CC	I-NP
O	1641	1645	time	time	NN	I-NP
O	1646	1651	since	since	IN	B-SBAR
O	1652	1655	the	the	DT	B-NP
O	1656	1660	burn	burn	NN	I-NP
O	1661	1674	significantly	significantly	RB	B-ADVP
O	1675	1676	(	(	(	O
O	1676	1677	p	p	NN	B-NP
O	1677	1678	<	<	SYM	B-ADJP
O	1678	1679	0	0	CD	B-NP
O	1679	1680	.	.	.	I-NP
O	1680	1682	05	05	CD	I-NP
O	1682	1683	)	)	)	O
O	1684	1692	affected	affect	VBD	B-VP
O	1693	1696	the	the	DT	B-NP
O	1697	1706	oxidative	oxidative	JJ	I-NP
O	1707	1712	burst	burst	NN	I-NP
O	1712	1713	.	.	.	O

B-Cell	1714	1719	White	White	JJ	B-NP
I-Cell	1720	1724	cell	cell	NN	I-NP
O	1725	1730	count	count	NN	I-NP
O	1731	1732	(	(	(	O
O	1732	1735	WCC	WCC	NN	B-NP
O	1735	1736	)	)	)	O
O	1737	1740	and	and	CC	O
O	1741	1742	C	C	NN	B-NP
O	1742	1743	-	-	HYPH	O
O	1743	1751	reactive	reactive	JJ	B-NP
O	1752	1759	protein	protein	NN	I-NP
O	1760	1761	(	(	(	O
O	1761	1764	CRP	CRP	NN	B-NP
O	1764	1765	)	)	)	O
O	1766	1772	values	value	NNS	B-NP
O	1773	1781	returned	return	VBD	B-VP
O	1782	1784	to	to	TO	B-PP
O	1785	1794	reference	reference	NN	B-NP
O	1795	1801	ranges	range	NNS	I-NP
O	1802	1806	long	long	JJ	B-ADJP
O	1807	1813	before	before	IN	B-PP
O	1814	1817	the	the	DT	B-NP
O	1818	1827	oxidative	oxidative	JJ	I-NP
O	1828	1833	burst	burst	NN	I-NP
O	1833	1834	.	.	.	O

O	1835	1846	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	1846	1847	:	:	:	O

O	1848	1852	This	This	DT	B-NP
O	1853	1858	study	study	NN	I-NP
O	1859	1867	provides	provide	VBZ	B-VP
O	1868	1876	evidence	evidence	NN	B-NP
O	1877	1881	that	that	IN	B-SBAR
O	1882	1899	immunosuppression	immunosuppression	NN	B-NP
O	1900	1902	in	in	IN	B-PP
O	1903	1908	those	those	DT	B-NP
O	1909	1916	injured	injure	VBN	B-VP
O	1917	1919	by	by	IN	B-PP
O	1920	1925	burns	burn	NNS	B-NP
O	1925	1926	,	,	,	O
O	1927	1929	as	as	IN	B-SBAR
O	1930	1938	assessed	assess	VBN	B-VP
O	1939	1941	by	by	IN	B-PP
O	1942	1945	the	the	DT	B-NP
O	1946	1948	in	in	FW	I-NP
O	1949	1954	vitro	vitro	FW	I-NP
O	1955	1964	oxidative	oxidative	JJ	I-NP
O	1965	1970	burst	burst	NN	I-NP
O	1971	1973	of	of	IN	B-PP
B-Cell	1974	1985	neutrophils	neutrophil	NNS	B-NP
O	1985	1986	,	,	,	O
O	1987	1994	remains	remain	VBZ	B-VP
O	1995	1999	long	long	JJ	B-ADJP
O	2000	2005	after	after	IN	B-SBAR
O	2006	2009	the	the	DT	B-NP
O	2010	2015	event	event	NN	I-NP
O	2016	2018	of	of	IN	B-PP
O	2019	2022	the	the	DT	B-NP
O	2023	2027	burn	burn	NN	I-NP
O	2028	2029	(	(	(	O
O	2029	2031	up	up	RB	B-ADVP
O	2032	2034	to	to	TO	B-PP
O	2035	2036	3	3	CD	B-NP
O	2036	2037	.	.	.	O
O	2037	2038	5	5	CD	B-NP
O	2039	2045	months	month	NNS	I-NP
O	2046	2051	after	after	IN	B-PP
O	2052	2056	burn	burn	NN	B-NP
O	2056	2057	)	)	)	O
O	2057	2058	.	.	.	O

O	2059	2066	Absence	Absence	NN	B-NP
O	2067	2069	of	of	IN	B-PP
O	2070	2082	correlations	correlation	NNS	B-NP
O	2083	2085	to	to	TO	B-PP
O	2086	2090	TBSA	TBSA	NN	B-NP
O	2090	2091	%	%	NN	I-NP
O	2091	2092	,	,	,	O
O	2093	2096	FTB	FTB	NN	B-NP
O	2096	2097	%	%	NN	I-NP
O	2097	2098	,	,	,	O
B-Organism_substance	2099	2104	blood	blood	NN	B-NP
O	2105	2116	transfusion	transfusion	NN	I-NP
O	2116	2117	,	,	,	O
O	2118	2125	opiates	opiate	VBZ	B-VP
O	2126	2134	provided	provide	VBN	I-VP
O	2134	2135	,	,	,	O
O	2136	2139	and	and	CC	O
O	2140	2148	multiple	multiple	JJ	B-NP
B-Organ	2149	2154	organ	organ	NN	I-NP
O	2155	2162	failure	failure	NN	I-NP
O	2163	2168	score	score	NN	I-NP
O	2169	2172	and	and	CC	O
O	2173	2183	laboratory	laboratory	NN	B-NP
O	2184	2193	infection	infection	NN	I-NP
O	2194	2203	variables	variable	NNS	I-NP
O	2204	2212	together	together	RB	B-ADVP
O	2213	2217	with	with	IN	B-PP
O	2218	2221	the	the	DT	B-NP
O	2222	2229	finding	finding	NN	I-NP
O	2230	2234	that	that	WDT	B-NP
O	2235	2244	decreased	decrease	VBD	B-VP
O	2245	2254	oxidative	oxidative	JJ	B-NP
O	2255	2260	burst	burst	NN	I-NP
O	2261	2264	was	be	VBD	B-VP
O	2265	2272	uniform	uniform	JJ	B-ADJP
O	2273	2278	after	after	IN	B-SBAR
O	2279	2282	the	the	DT	B-NP
O	2283	2289	injury	injury	NN	I-NP
O	2289	2290	,	,	,	O
O	2291	2301	suggesting	suggest	VBG	B-VP
O	2302	2306	that	that	IN	B-SBAR
O	2307	2311	this	this	DT	B-NP
O	2312	2329	immunosuppression	immunosuppression	NN	I-NP
O	2330	2332	is	be	VBZ	B-VP
O	2333	2342	primarily	primarily	RB	B-ADJP
O	2343	2346	due	due	JJ	I-ADJP
O	2347	2349	to	to	TO	B-PP
O	2350	2353	the	the	DT	B-NP
O	2354	2361	general	general	JJ	I-NP
O	2362	2371	metabolic	metabolic	JJ	I-NP
O	2372	2380	response	response	NN	I-NP
O	2381	2387	rather	rather	RB	B-CONJP
O	2388	2392	than	than	IN	I-CONJP
O	2393	2402	recurring	recur	VBG	B-VP
O	2403	2413	infections	infection	NNS	B-NP
O	2413	2414	.	.	.	O

